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Background: Prospective studies have shown that low levels of circulating insulin-like growth factor binding
protein-1 (IGFBP-1) are associated with the risk of type 2 diabetes. In the present study, we investigated DNA
methylation in the IGFBP1 gene to evaluate its changes in relation to serum IGFBP-1 levels in type 2 diabetes.
Results: A total of 406 Swedish men, including age-matched normal glucose tolerance subjects and type 2
diabetes patients either newly diagnosed or undergoing treatment, were selected from the Stockholm Diabetes
Prevention Program. IGFBP1 methylation levels in genomic DNA extracted from peripheral blood were analysed
by bisulfite pyrosequencing. Serum IGFBP-1 levels were measured by radio-immunoassay. We found that IGFBP1
DNA methylation levels were higher in both newly diagnosed and treated type 2 diabetes patients with a mean
diabetes duration of 3 years compared with subjects with normal glucose tolerance (19.8% and 20.2% vs. 16.9%,
P < 0.001 for both). Serum levels of IGFBP-1 in newly diagnosed and in treated type 2 diabetes patients were
lower compared with healthy individuals (18 μg/l both vs. 24 μg/l, P = 0.011, P < 0.001). IGFBP1 methylation
levels but not serum IGFBP-1 levels in type 2 diabetes patients were independent of body mass index. Newly
diagnosed patients with a family history of diabetes (FHD) had higher IGFBP1 methylation levels than those
without FHD (20.3% vs. 18.6%, P = 0.017).
Conclusions: This study provides the first evidence that changes in DNA methylation of the IGFBP1 gene are
associated with type 2 diabetes in Swedish men and suggests that increased IGFBP1 DNA methylation and
decreased IGFBP-1 serum levels are features of type 2 diabetes with a short duration.
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Type 2 diabetes mellitus is a complex metabolic disorder
influenced by genetic and environmental factors. In recent
years, genome-wide association studies (GWAS) have
identified a number of confirmed genetic susceptibility
variants for type 2 diabetes. However, GWAS findings can
only explain approximately 10% of the overall heritable
risk of type 2 diabetes, which challenges our expectations* Correspondence: tianwei.gu@ki.se
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reproduction in any medium, provided the orfor translating genetic information into clinical practice
[1-3]. One of the reasons for the missing information on
heritability could be that epigenetic factors are involved in
the complex interplay between genes and environment.
Knowledge of the epigenetic factors associated with type 2
diabetes is still limited. Therefore, epigenetic studies may
provide further information to give a better understanding
of the pathogenesis of type 2 diabetes [4-6].
The circulating insulin-like growth factor binding
protein-1 (IGFBP-1), produced in the liver, has an inhibi-
tory effect on the action of insulin-like growth factors
and is mainly regulated by portal insulin [7,8]. ClinicalThis is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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level of IGFBP-1 is associated with insulin resistance, type
2 diabetes and the metabolic syndrome [9-11]. We have
previously analysed IGFBP-1 serum levels in Swedish
middle-aged and elderly twins and found that environmen-
tal influences predominate for IGFBP-1 levels [12]. We
have also demonstrated that a low serum level of IGFBP-1
predicts the development of type 2 diabetes in middle-aged
Swedish men and women [9,13,14].
DNA methylation variation is hypothesized to alter indi-
vidual susceptibility to type 2 diabetes [4]. DNA methyla-
tion levels are commonly analysed at clusters of CpG
methylation sites in the genes and used to indicate epigen-
etic effects [15]. However, there are no reports from
epigenetic studies of IGFBP1 in type 2 diabetes. It is un-
known whether DNA methylation patterns of the IGFBP1
gene are associated with type 2 diabetes. In this study, we
investigated DNA methylation levels of the IGFBP1 gene
in Swedish men, including subjects with normal glucose
tolerance or type 2 diabetes and analysed serum IGFBP-1
levels. Our study demonstrates that increased IGFBP1
methylation levels and reduced protein levels are associ-
ated with type 2 diabetes.
Results
Association of IGFBP1 DNA methylation and IGFBP-1
serum levels with type 2 diabetes
We conducted genomic DNA methylation analyses of
six CpG sites in the human IGFBP1 gene. The IGFBP1
DNA methylation levels at each of the six CpG sitesFigure 1 DNA methylation and serum levels of IGFBP1 in Swedish me
DNA methylation levels at each of the six CpG sites in patients with newly dia
significantly higher compared with those in non-diabetic control subjects (P <
six CpG sites together as total, significantly increased DNA methylation levels o
in comparison with the controls were found (18.9%, 19.8% and 16.9%, respecti
IGFBP-1 levels were significantly higher in non-diabetic control subjects t
diabetes. P values: * < 0.05, *** < 0.001. IGFBP-1, insulin-like growth factor bindwere significantly higher in both newly diagnosed type 2
diabetes patients (P1 24.3%, P2 17.5%, P3 15.0%, P4
16.4%, P5 21.3% and P6 24.7%) and treated patients (P1
24.6%, P2 18.2%, P3 15.8%, P4 16.2%, P5 21.6% and P6
24.7%) compared with those in non-diabetic subjects
(P1 17.7%, P2 15.6%, P3 12.7%, P4 13.%, P5 19.5% and
P6 22.%) (P < 0.001 for all comparisons vs. non-
diabetic controls) (Figure 1A). Combining all six CpG
sites together, the mean values of IGFBP1 DNA methy-
lation levels were significantly increased in both newly
diagnosed and treated patients in comparison with
non-diabetic subjects (19.8%, 18.9% and 16.9%, P <
0.001 for both type 2 diabetes groups vs. controls)
(Figure 1B). However, there were no differences in
DNA methylation levels at any CpG site of the IGFBP1
gene between newly diagnosed patients and the pa-
tients on treatments. Further analyses were performed
according to the different treatments given to the
treated type 2 diabetes patients. IGFBP1 DNA methy-
lation levels were similar in the treatment groups
(20.7% in patients on physical exercise and diet con-
trol, 19.4% in patients on oral anti-diabetic drugs
(OADs), 20.4% in patients on insulin treatment and
19.4% in patients on OADs + insulin).
We further analysed fasting serum IGFBP-1 levels
and found that newly diagnosed and treated patients
with type 2 diabetes had similar fasting serum IGFBP-1
levels (18 μg/l in both groups), which were significantly
lower than those in non-diabetic control subjects (24 μg/l,
P = 0.011 and P < 0.001, respectively) (Figure 1C).n with normal glucose tolerance and type 2 diabetes. (A) IGFBP1
gnosed type 2 diabetes and in patients undergoing treatment were
0.001 for all comparisons with non-diabetic subjects). (B) Combining all
f the IGFBP1 gene in newly diagnosed and treated type 2 diabetes patients
vely, P< 0.001 for both type 2 diabetes group vs. controls.) (C) Serum
han in both newly diagnosed and treated patients with type 2
ing protein-1; NGT, normal glucose tolerance; T2D, type 2 diabetes.
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serum levels with family history of diabetes
To understand whether IGFBP1 DNA methylation and
serum IGFBP-1 levels are related to a family history of
diabetes (FHD), we carried out comparison analyses be-
tween subjects with and without FHD. The data showed
that non-diabetic control subjects with FHD had similar
IGFBP1 DNA methylation levels (16.9% and 17.0%) but
lower serum protein levels compared with those with-
out FHD (19 vs. 25 μg/L, P = 0.018) (Figure 2A and 2B).
Newly diagnosed type 2 diabetes patients with FHD had
significantly increased IGFBP1 DNA methylation levels
compared with the patients without FHD (20.3% vs.
18.6%, P = 0.017) (Figure 2A). Although the geometric
mean values of IGFBP-1 serum levels in newly diag-
nosed type 2 diabetes patients with FHD appeared lower
compared with the patients without FHD, no significant
difference was detected. Moreover, newly diagnosed pa-
tients with FHD had higher glucose (8.1 vs. 6.5 mmol/l,
P = 0.007) and higher insulin levels (179.1 vs. 138.3
pmol/l, P = 0.021) compared to patients without FHD
(Figure 2B). There were no differences in the levels of
IGFBP1 DNA methylation, serum IGFBP-1, glucose orFigure 2 DNA methylation and serum levels of IGFBP1 according to f
history of diabetes (FHD) (0), non-diabetic control subjects with FHD (1) ha
A) but significantly lower serum protein levels (19 vs. 25 μg/L, P = 0.018) (B
increased IGFBP1 DNA methylation levels (20.3% vs. 18.6%, P = 0.014) (A), h
pmol/l, P = 0.022) levels compared to patients without FHD (B). There were
glucose or insulin between treated type 2 diabetes patients with and witho
glucose tolerance; T2D, type 2 diabetes.insulin between treated type 2 diabetes patients with
and without FHD.
Association of IGFBP1 DNA methylation and IGFBP-1
serum levels with body weight
To further investigate whether changes of IGFBP1 DNA
methylation levels were related to body weight in type 2
diabetes, we conducted analyses according to body mass
index (BMI). Subjects were divided into subgroups based
on a BMI cut-off of 25 kg/m2. There were no differences
in the IGFBP1 DNA methylation levels between lean
(BMI < 25 kg/m2) and overweight/obese (BMI ≥ 25 kg/m2)
subjects in any of the three groups (Figure 3A). However,
compared with overweight/obese subjects, lean individuals
in the control group and newly diagnosed patients had sig-
nificantly higher serum IGFBP-1 levels (29 vs. 22 μg/l, P =
0.022; 29 vs. 16 μg/l, P = 0.011) and lower insulin levels
(86.6 vs. 100.6 pmol/l, P = 0.011; 98.9 vs. 181.5 pmol/l, P <
0.001) (Figure 3B). No differences were found in fasting
glucose levels between lean and overweight/obese subjects
within any group.
We also conducted similar analyses for waist circum-
ference with a cut-off at 94 cm. Data showed that thereamily history of diabetes. Compared with those without a family
d similar IGFBP1 DNA methylation levels (16.9% vs. 17.0%, P = 0.895,
). Newly diagnosed type 2 diabetes patients with FHD had significantly
igher glucose (8.1 vs. 6.5 mmol/l, P = 0.007) and insulin (153.6 vs. 118.8
no differences in levels of IGFBP1 DNA methylation, serum IGFBP-1,
ut FHD. P value: * < 0.05. FHD, family history of diabetes; NGT, normal
Figure 3 DNA methylation and serum levels of IGFBP1 according to body mass index. (A) No differences were found in the IGFBP1 DNA
methylation levels between lean and overweight/obese subjects in non-diabetic control subjects, newly diagnosed and treated type 2 diabetes patients.
(B) However, lean individuals had significantly higher serum IGFBP-1, lower insulin and similar glucose levels compared with subjects who were
overweight/obese. BMI, body mass index; IGFBP-1, insulin-like growth factor binding protein-1; NGT, normal glucose tolerance; T2D, type 2 diabetes.
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levels between subjects with waists <94 cm and ≥94 cm
within any group: non-diabetic control subjects (16.6% vs.
17.1%, P = 0.307), newly diagnosed (19.7% vs. 20.2%, P =
0.551) and treated type 2 diabetes patients (20.3% vs.
19.8%, P = 0.607).
Correlation between IGFBP1 DNA methylation levels and
IGFBP-1 serum levels
We analysed the correlation between IGFBP1 DNA methy-
lation levels and IGFBP-1 serum levels. A borderline signifi-
cant correlation between IGFBP1 DNA methylation levels
and IGFBP-1 serum levels was found in non-diabetic sub-
jects (r = 0.186, P = 0.050), but not in newly diagnosed type
2 diabetes patients (P = 0.770) or patients undergoing treat-
ment (P = 0.230).
Discussion
We conducted an epigenetic study of the human IGFBP1
gene in Swedish men with and without type 2 diabetes in
parallel with analyses of fasting IGFBP-1 protein levels in
serum. Our results demonstrated that compared with non-
diabetic controls, DNA methylation levels of the IGFBP1
gene were higher in all type 2 diabetes patients, while
IGFBP-1 serum levels were lower. Newly diagnosed type 2diabetes patients with FHD had higher DNA methylation
levels compared with those without FHD. Furthermore,
IGFBP1 DNA methylation levels were found to be inde-
pendent of BMI or waist circumference, while IGFBP-1
serum levels were inversely related to BMI.
It has been shown that DNA methylation is influenced by
age, gender, genetic background, lifestyle and body weight
[16-18]. To avoid the influence of age and gender, for our
study we selected age-matched Swedish men including
non-diabetic subjects, newly diagnosed type 2 diabetes pa-
tients not taking medication and patients undergoing treat-
ment, from the Stockholm Diabetes Prevention Program
(SDPP) cohort. There is a CpG island in the regions of the
promoter and 5’-UTR of the IGFBP1 gene. By using well-
selected and characterized subjects, we analysed six CpG
sites in 5’-UTR, which may represent the methylation levels
of IGFBP1. A previous study has demonstrated that high
CpG density region at 5’-UTR recruits a methy-CpG bind-
ing protein to the promoter and represses gene transcrip-
tion [19]. We found increased DNA methylation in all type
2 diabetes patients, who also had decreased circulating
levels of IGFBP-1. However, we were not able to establish
the causal relationship between IGFBP1 DNA methylation
alteration and the development of type 2 diabetes from the
current cross-sectional study. We further compared the
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tients on different treatments, including diet, OAD, insulin
and insulin plus OAD. There were no significant differ-
ences between the subgroups, suggesting no effect of dia-
betes treatment on IGFBP1 methylation levels. This could
be due to the limited duration of type 2 diabetes in these
patients (mean 3 years) and also that the numbers of indi-
viduals in the subgroups were relatively small.
In this study, we measured the fasting morning levels
of IGFBP-1, which reflects IGFBP-1 secretion over the
previous 24 hours and overall endogenous and exogen-
ous insulin effect during the previous 24 hours [20]. Low
serum IGFBP-1 levels are associated with hyperinsuline-
mia and subsequently with overweight or obesity [13,14].
We thus stratified the subjects according to BMI and
waist circumference. The were no differences in the
IGFBP1 DNA methylation levels for any of the three
groups, suggesting that the variation of IGFBP1 DNA
methylation was due to the type 2 diabetes, rather than
being overweight or obese. In addition, we analysed the
IGFBP1 DNA methylation levels according to lifestyle
factors including smoking status, physical activity levels
and alcohol consumption. We found no significant dif-
ferences within any group (data not shown).
When evaluating IGFBP1 DNA methylation levels in
type 2 diabetes patients according to FHD, we found
that newly diagnosed patients with FHD not only had
higher fasting glucose and insulin levels but also in-
creased IGFBP1 DNA methylation. This implies that
there could be a trans-generation effect in patients with
FHD. Furthermore, newly diagnosed patients with FHD
had hyperinsulinemia and impaired glucose tolerance
for a longer time before diagnosis compared with those
without FHD [21].
There are limitations of the present study. First, there
is the lack of human liver tissue samples for methyla-
tion analysis. We do not know whether IGFBP1 DNA
methylation levels in peripheral blood cells do reflect
its methylation levels in the liver. However, we ob-
served a weak correlation between IGFBP1 DNA
methylation levels in peripheral blood cells and circu-
lating IGFBP-1 serum levels in non-diabetic subjects.
Type 2 diabetes is a complex disease. The correlation
between DNA methylation and serum protein levels is
influenced by multiple factors, which may explain the
lack of correlation between IGFBP1 DNA methylation
and serum IGFBP-1 levels in type 2 diabetes patients.
Second, our patients had diabetes for only a short time.
Therefore, the effects of diabetes treatment on DNA
methylation might be too trivial to detect. Analyses of
liver-tissue-specific DNA methylation levels, gene tran-
scription in liver cell lines after RNA interference at
CpG sites and using patients with longstanding dia-
betes are being considered for further investigation.Conclusions
In this study, we provide the first evidence that DNA
methylation changes of the IGFBP1 gene are associated
with type 2 diabetes in Swedish men with a short dur-
ation. Taking our present study and recent reports to-
gether, we also suggest that increased IGFBP1 DNA
methylation and decreased IGFBP-1 serum levels are
features of type 2 diabetes.
Methods
Subjects
A sample of Swedish men, comprising 242 subjects with
normal glucose tolerance (non-diabetic controls) and 164
patients with type 2 diabetes, was studied. They were all
participants of SDPP and lived in the municipalities of
Värmdö, Upplands-Bro, Tyresö or Sigtuna in Stockholm
County [22]. The subjects with normal glucose tolerance
were age-matched with type 2 diabetes patients (mean age
58 years). Of the patients, 89 were newly diagnosed and
not receiving medication when the clinical data were re-
corded. The other 75 patients had had diabetes for a mean
of 3 years and were being treated with advice on physical
exercise and diet control (29.3%), OADs (53.3%), insulin
(5.3%) or a combination of these (4.0%). In SDPP, informa-
tion on smoking status, physical activity levels and alcohol
consumption were recorded for all participants based
upon questionnaires [22].
All patients with type 2 diabetes in SDPP were diag-
nosed according to the World Health Organization
(WHO) criteria [23]. FHD was defined as having at least
one first-degree relative (parent or sibling) or at least two
second-degree relatives (grandparents, uncles or aunts)
with diabetes. The clinical characteristics of the subjects
are summarized in Table 1. All data shown are means
(95% CI) except fasting insulin where geometric means
(95% CI) are given. P values from Tukey post hoc tests
were between type 2 diabetes patients either newly diag-
nosed or receiving treatment and non-diabetic controls.
No differences were found between newly diagnosed pa-
tients and patients receiving treatment.
Informed consent has been received from all participants.
The study has been approved by the Ethics Committee of
Karolinska University Hospital and was performed in ac-
cordance with the Declaration of Helsinki II.
DNA extraction and bisulfite treatment
We analysed human IGFBP1 DNA methylation levels in
genomic DNA samples. Genomic DNA was extracted
from peripheral blood in all subjects using the Gentra
Puregene Blood Kit (Qiagen, Hilden, Germany), which en-
ables purification of high molecular weight DNA (100 kb
to 200 kb) suitable for archiving. The scalable purification
procedure gently removes contaminants and inhibitors
and large-volume samples can be purified for genetic and
Table 1 Clinical characteristics of Swedish men with normal glucose tolerance or type 2 diabetes
Characteristic Non-diabetic subjects Patients with newly diagnosed
type 2 diabetes
Patients with type 2
diabetes receiving treatment
N 242 89 75
(FHD −/+) (178/64) (26/63) (12/63)
Age (years) 58 (57–58) 58 (57–59) 59 (58–60)
BMI (kg/m2) 26.1 (25.9–26.3) 29.3 (28.4–30.3)*** 30.5 (29.4–31.5)***
WC (cm) 93.2 (92.4–94.0) 101.8 (99.4–104.3)*** 103.7 (101.2–106.2)***
Glucose (mmol/L) 5.0 (4.9–5.1) 7.6 (7.1–8.1)*** 8.3 (8.1–9.0)***
Insulin (pmol/L) 96.7 (91.9–101.8) 166.1 (150.0–157.8)*** 160.0 (140.0–181.8)***
SBP (mmHg) 135 (134–138) 145 (141–149)*** 145 (141–149)***
DBP (mmHg) 83 (82–84) 88 (86–90)*** 87 (85–89)*
IGF-I (ug/L) 171 (162–180) 162 (151–172) 156(147–166)
BMI, body mass index; WC, waist circumference; DBP, diastolic blood pressure; FHD, family history of diabetes; IGF, insulin-like growth factor; SBP, systolic blood pressure.
P values: * < 0.05, ** < 0.01 and *** < 0.001.
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was stored at −80°C until use. For epigenetic analysis, the
extracted DNA samples were bisulfite treated using the
EpiTect Bisulfite Kit (Qiagen). This kit gives complete
conversion of unmethylated cytosine to uracil and subse-
quent purification in less than 6 hours. This highly sensi-
tive method utilizes an innovative protection against DNA
degradation and ensures high conversion rates of over
99%. DNA extraction and bisulfite treatment were con-
ducted according to the manufacturer’s instructions.IGFBP1 DNA methylation analyses
There is a CpG island in the promoter and exon 1 of
the IGFBP1 gene. We used a PyroMark CpG assay
(ENSG00000146678, Qiagen) and PyroMark PCR kit (Qia-
gen) for the IGFBP1 gene methylation analysis, which in-
cluded six CpG sites (CGAGCATCTGCCGCCGCGCC
GCCGCCACC) at 5′-UTR of the IGFBP1 gene as indi-
cated with the bold letter “C” and referred to as P1 to P6
(P is the position). DNA methylation in mammals is nor-
mally found as 5-methyl cytosine followed by guanosine
[15]. The PyroMark PCR Master Mix includes HotStarTaq
DNA polymerase and the optimized PyroMark reaction
buffer containing 3 mM MgCl2 and Deoxynucleotidse
(dNTPs), 10× CoralLoad concentrate, 5× Q-Solution, 25
mM MgCl2, and RNase-free water. The PCR amplicon
length was 177 bp and covers the sequence in human
chromosome 7:45928112–45928134 (version 37.56). The
methylation levels of these CpG sites were detected using
the PyroMark Gold 96 Reagent Kit (Qiagen, Hilden,
Germany) and the PyroMark Q96 ID pyrosequencing sys-
tem (Biotage, Uppsala, Sweden). Pyrosequencing methyla-
tion analysis of CpG sites is a sensitive and accurate
protocol [24,25]. PyroQ-CpG software (Biotage) was used
for methylation data analysis. Unmethylated bisulfite con-
verted and unconverted DNAs (Qiagen) were used tomonitor the conversion efficiency of the bisulfite treat-
ment and the accuracy of the methylation analyses.
Assays for serum protein analyses
Serum samples from all subjects were included in protein
analyses. Fasting serum IGFBP-1 and insulin levels were de-
termined using in-house radio-immunoassays (RIAs) with
polyclonal antibodies for human IGFBP-1 and insulin, re-
spectively, as previously described [26,27]. The IGFBP-1
protein in serum samples stored at −20°C is stable. The
intra- and inter-assay coefficients of variation (CV) values
were 3% and 10%, respectively [13]. Serum IGF-1 levels
were measured using an in-house RIA after acid-ethanol
extraction and cryoprecipitation. To minimize interference
by IGFBPs, des IGF-1 was used as a tracer as previously de-
scribed [28]. The intra- and inter-assay CV values were 4%
and 11%, respectively.
Statistical analyses
Data presented in the table and figures are either means
with 95% confidence interval (CI) or geometrical means
with 95% CI if the data were not normally distributed.
Tests for comparison of continuous variables between
groups were assessed using an unpaired t-test or one-way
ANOVA followed with Tukey’s post hoc test. Data in non-
normally distributed traits were transformed to the natural
logarithm to give a normal distribution before the statis-
tical analysis was performed. Linear regression analysis
was used to examine the relation between variables. A
P value less than 0.05 was considered as significant. All
data were analysed using the PASW statistic program
(SPSS 20.0, Chicago, IL, USA).
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